You are here

Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Hospital Santa Izabel - Santa Casa de Misericórdia da Bahia
Salvador, Bahia, 40050-410 Brazil
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Subject has a minimum 1 year history/diagnosis of rheumatoid arthritis based on the
1987 American College of Rheumatology (ACR) Revised criteria for RA.

2. Subject must have active rheumatoid arthritis despite methotrexate (MTX) therapy of
≥10 mg/wk for at least 12 weeks. The MTX dose must be stable for at least 4 weeks
immediately prior to screening.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Subjects who used any of the following systemic treatments during the washout periods
given below:

1. Oral corticosteroid dose of prednisone >7.5 mg/day (or equivalent) or a change in
dose within 28 days of baseline.

2. Treatment with more than 1 NSAID within 14 days at baseline.

3. Methotrexate dose greater than 25 mg/week, or change in the dose of methotrexate
within 28 days of baseline.

4. Subjects will be allowed to continue the following non biologic DMARDs:
sulfasalazine, hydroxychloroquine, and leflumomide. All other non-biologic DMARDs
(including but not limited to gold, penicillamine, azathioprine,
cyclophospamide), and biologic DMARDs must have been discontinued at least 2
months prior to Week 1.

5. Any biologic B cell depleting agent (eg, rituximab) within 2 years of Week 1.

2. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.

3. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.

NCT01578850
Pfizer
Completed
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
A Randomized, Double-blind Placebo-controlled Study Of The Maintenance Of Efficacy Of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone In Subjects With Rheumatoid Arthritis After Achieving An Adequate Response With Etanercept Plus Dmard(s)
To compare the maintenance of efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with or without other disease modifying antirheumatic drugs therapy with that of methotrexate with or without other disease modifying antirheumatic drugs therapy at Week 52 in subjects with moderately to severely active rheumatoid arthritis who have achieved low disease activity after 24 weeks of therapy with open label etanercept 50 mg once weekly plus MTX with or without other disease modifying antirheumatic drugs therapy.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Drug: Etanercept
    etanercept 50mg once weekly + methotrexate with or without other DMARDs
  • Drug: placebo
    etanercept placebo once weekly + methotrexate with or without other DMARDs
  • Experimental: Group A
    Intervention: Drug: Etanercept
  • Placebo Comparator: Group B
    Intervention: Drug: placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
491
March 2015
March 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject has a minimum 1 year history/diagnosis of rheumatoid arthritis based on the 1987 American College of Rheumatology (ACR) Revised criteria for RA.
  2. Subject must have active rheumatoid arthritis despite methotrexate (MTX) therapy of ?10 mg/wk for at least 12 weeks. The MTX dose must be stable for at least 4 weeks immediately prior to screening.

Exclusion Criteria:

  1. Subjects who used any of the following systemic treatments during the washout periods given below:

    1. Oral corticosteroid dose of prednisone >7.5 mg/day (or equivalent) or a change in dose within 28 days of baseline.
    2. Treatment with more than 1 NSAID within 14 days at baseline.
    3. Methotrexate dose greater than 25 mg/week, or change in the dose of methotrexate within 28 days of baseline.
    4. Subjects will be allowed to continue the following non biologic DMARDs: sulfasalazine, hydroxychloroquine, and leflumomide. All other non-biologic DMARDs (including but not limited to gold, penicillamine, azathioprine, cyclophospamide), and biologic DMARDs must have been discontinued at least 2 months prior to Week 1.
    5. Any biologic B cell depleting agent (eg, rituximab) within 2 years of Week 1.
  2. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.
  3. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Brazil,   China,   Colombia,   Czech Republic,   Egypt,   Hungary,   Jordan,   Lebanon,   Malaysia,   Mexico,   Philippines,   Qatar,   Romania,   Russian Federation,   South Africa,   Taiwan,   Thailand,   Ukraine,   United Arab Emirates
Saudi Arabia
 
NCT01578850
B1801315
2011-005448-87 ( EudraCT Number )
B1801315 ( Other Identifier: Alias Study Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2016

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now